Spots Global Cancer Trial Database for apl
Every month we try and update this database with for apl cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
AIDA 2000 Guidelines | NCT01064570 | Acute Promyeloc... | all-trans retin... | 1 Year - 60 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
AIDA 2000 Guidelines | NCT01064570 | Acute Promyeloc... | all-trans retin... | 1 Year - 60 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers | NCT00421213 | Hematologic Neo... Bone Marrow Neo... Non-Hodgkin's L... | Darinaparsin | 18 Years - | Alaunos Therapeutics | |
A Safety Study of SGN-CD33A in AML Patients | NCT01902329 | Acute Myelogeno... Acute Myeloid L... Acute Promyeloc... | HMA SGN-CD33A | 18 Years - | Seagen Inc. | |
All-trans Retinoic Acid, and Arsenic +/- Idarubicin | NCT00413166 | Acute Promyeloc... | All-Trans Retin... Arsenic Trioxid... Idarubicin Gemtuzumab Ozog... | - | M.D. Anderson Cancer Center | |
Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia | NCT00675870 | Acute Promyeloc... | NRX 195183 Soft... | 18 Years - | NuRx Pharmaceuticals, Inc. | |
Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers | NCT00421213 | Hematologic Neo... Bone Marrow Neo... Non-Hodgkin's L... | Darinaparsin | 18 Years - | Alaunos Therapeutics | |
A Randomized Trial Assessing the Roles of AraC in Newly Diagnosed APL Promyelocytic Leukemia (APL) | NCT00591526 | Leukemia, Promy... | Arac | - | Groupe d'etude et de travail sur les leucemies aigues promyelocytaires | |
A Safety Study of SGN-CD33A in AML Patients | NCT01902329 | Acute Myelogeno... Acute Myeloid L... Acute Promyeloc... | HMA SGN-CD33A | 18 Years - | Seagen Inc. | |
Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia | NCT00675870 | Acute Promyeloc... | NRX 195183 Soft... | 18 Years - | NuRx Pharmaceuticals, Inc. | |
Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL | NCT00520208 | Acute Promyeloc... | Tamibarotene | 18 Years - | CytRx | |
APL93: Timing of CxT and Role of Maintenance | NCT00599937 | Leukemia, Promy... | ATRA ATRA and or Che... | - | Groupe d'etude et de travail sur les leucemies aigues promyelocytaires | |
Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia | NCT05881265 | APL | Chidamide+venet... | 16 Years - 70 Years | Shanghai Jiao Tong University School of Medicine | |
A Randomized Trial Assessing the Roles of AraC in Newly Diagnosed APL Promyelocytic Leukemia (APL) | NCT00591526 | Leukemia, Promy... | Arac | - | Groupe d'etude et de travail sur les leucemies aigues promyelocytaires |